1. Introduction {#sec1}
===============

Unlike other ginsenosides with various pharmacological activities (e.g., ginsenoside Rg3) [@bib1; @bib2], ginsenoside Rp1 (G-Rp1) is a ginseng saponin artificially prepared from crude ginsenosides (e.g., G-Rg5 and G-Rk1) obtained from *Panax ginseng* Meyer by reduction and hydrogenation [@bib3]. The phytochemical features of G-Rp1 include its chemical stability, and various pharmacological approaches have suggested its value as a biologically active ginsenoside. It has been reported that G-Rp1 is able to prevent skin papillomagenesis induced by 7,12-dimehtylbenz(a) anthracene [@bib4], suppress the proliferation and metastatic processes of cancer cells [@bib5], and reverse multidrug resistance in tumor cells [@bib6]. In addition, G-Rp1 has also been found to block interleukin-1 production and diminish platelet activation and thrombus formation [@bib7; @bib8]. It has also been revealed that G-Rp1 blocks pathways linked to multidrug resistance gene-1 (MRD-1), Src, Akt, and I-kappaB kinase (IKK) in apoptotic and inflammatory processes [@bib6; @bib9; @bib10]. Although these experiments have explored the potential mechanisms underlying the anticancer and anti-inflammatory activities of G-Rp1, the proteins responsible for these pharmacological actions remain unclear. Therefore, in this study, we used proteomic analysis to investigate the effect of G-Rp1 on the protein profiles and expression levels in several cancer cells to understand the mechanisms underlying its anticancer activity.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

G-Rp1 ([Fig. 1](#fig1){ref-type="fig"}) of 97% purity dissolved in 100% dimethylsulfoxide was prepared using established protocols [@bib3]. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and propidium iodide (PI) were purchased from Sigma--Aldrich (St. Louis, MO, USA). Polyvinylidenedifluoride membrane was purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA). Phospho- or total antibodies to apolipoprotein (Apo)-A1, cleaved poly(ADP-ribose) polymerase (c-PARP), p85/phosphoinositide 3-kinase, AKT, extracellular signal-regulated kinase (ERK), Src, p65/nuclear factor-κB, p53 and β-actin were purchased from Cell Signaling (Beverly, MA, USA). LoVo, SNU-407, DLD-1, SNU-638, AGS, KPL-4, and SK-BR-3 cells were obtained from the Korean Cell Line Bank (Seoul, Korea).

2.2. Cell lines and culture {#sec2.2}
---------------------------

LoVo, SNU-407, DLD-1, SNU-638, AGS, KPL-4, and SK-BR-3 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (Gibco, Grand Island, NY, USA) and an antibiotic cocktail (100 U/mL penicillin and 100 μg/mL streptomycin), and were subcultured by trypsinization every 3--4 days. Cells were grown at 37°C and 5% CO~2~ in humidified air.

2.3. Two-dimensional gel electrophoresis-based comparative proteomics {#sec2.3}
---------------------------------------------------------------------

Two-dimensional gel electrophoresis (2-DE) analysis was performed as described previously [@bib10]. A 0.15-mg protein sample was applied to 13-cm immobilized nonlinear gradient strips (pH 3--10), focused at 8,000 V within 3 hours, and separated on 10% polyacrylamide gels (Serva, Heidelberg, Germany; Bio-Rad). The 2-DE gels were stained with Colloidal Coomassie Blue (Invitrogen, Carlsbad, CA, USA) for 24 hours and then destained with deionized water. Proteins showing abnormal expression were subjected to matrix-associated laser desorption/ionization--mass spectroscopy (MALDI-MS) analysis for identification.

2.4. Cell viability assay {#sec2.4}
-------------------------

After preincubation of LoVo cells (1×10^6^ cells/mL) for 18 hours, G-Rp1 (0--60μM) was added to the cell suspensions and incubated for 24 hours. The cytotoxic effect of G-Rp1 was then evaluated using a conventional MTT assay, as previously reported [@bib11; @bib12]. Three hours prior to culture termination, 10 mL MTT solution (10 mg/mL in phosphate-buffered saline, pH 7.4) was added, and the cells were continuously cultured until termination of the experiment. Incubation was halted by addition of 15% sodium dodecyl sulfate (SDS) into each well, solubilizing the formazan [@bib13]. The absorbance at 570 nm (OD~570--630~) was measured using a Spectramax 250 microplate reader (BioTex, Bad Friedrichshall, Germany).

2.5. Flow-cytometric analysis of DNA fragmentation {#sec2.5}
--------------------------------------------------

Flow-cytometric analysis for PI staining was performed as described previously [@bib14; @bib15]. LoVo (10^6^) cells were washed with PBS, fixed in ethanol, suspended in PI solution (1 mg/mL RNase A, 50 micro g/mL PI, and 0.1% Triton X-100 in 3.8mM sodium citrate) and incubated on ice for 30 minutes in the dark. After washing three times with fluorescence activated cell sorting (FACS) buffer, PI fluorescent intensity was analyzed on a FACScan (Becton Dickinson, Franklin Lakes, NJ, USA).

2.6. 2-DE {#sec2.6}
---------

LoVo cells incubated with G-Rp1 were harvested and suspended in 0.5 mL sample buffer consisting of 40mM Tris, 5M urea (Merck, Darmstadt, Germany), 2M thiourea (Sigma--Aldrich), 4% 3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate (Sigma--Aldrich), 10mM dithiothreitol (Merck), 1mM EDTA (Merck), and a mixture of protease inhibitors (Roche Diagnostics, Basel, Switzerland) for 45 minutes at room temperature. After centrifugation at 16,000 *g* for 15 minutes, 150 μg protein was dissolved in rehydration buffer and applied to both the basic and acidic ends of the 13-cm immobilized pH 3--10 nonlinear gradient strips (Life Technologies, Carlsbad, CA, USA). Proteins were focused at 8,000 V within 3 hours. Immobilized pH gradient strips were rehydrated using 250 μL of each paired preparation. Once isoelectric focusing was completed, the strips were equilibrated in equilibration buffer for 10 minutes. The second dimension was performed using 10% SDS-polyacrylamide gel electrophoresis (PAGE) at 20 mA per gel. The gels were stained using a colloidal blue staining kit (Life Technologies) for 24 hours, and destained with deionized water. Melanie 7.0 software (Swiss Institute of Bioinformatics, Geneva, Switzerland) was used for protein pattern evaluation analysis of the 2-DE gels, as reported previously [@bib16]. Proteins with abnormal levels were subjected to MALDI-MS analysis for identification.

2.7. Mass analysis and data alignment {#sec2.7}
-------------------------------------

2-DE gels containing the proteins of interest were excised, destained, and dried in a SpeedVac evaporator (Thermoscientific, Waltham, MA, USA). Dried gel pieces were rehydrated with 30 μL 25mM sodium bicarbonate containing 50 ng trypsin (Promega, Madison, WI, USA) at 37°C overnight. α-Cyano-4-hydroxycinnamic acid (10 mg; AB Sciex, Foster City, CA, USA) was dissolved in 1 mL 50% acetonitrile in 0.1% trifluoroacetic acid, and 1 μL of the matrix solution was mixed with an equivalent volume of sample. Analysis was performed using a 4700 Proteomics Analyzer TOF/TOF system (AB Sciex). The TOF/TOF system was set to positive ion reflect mode. Mass spectra were first calibrated in the closed external mode using the 4700 proteomics analyzer calibration mixture (AB Sciex) and analyzed with GPS Explorer software, version 3.5 (AB Sciex). The acquired MS/MS spectra were searched against SwissProt and NCBI databases using an in-house version of MASCOT.

2.8. Preparation of cell lysates and nuclear fractions for immunoblotting and immunoprecipitation {#sec2.8}
-------------------------------------------------------------------------------------------------

Cancer cells (5 × 10^6^ cells/mL) were washed three times in cold PBS containing 1mM sodium orthovanadate and lysed in lysis buffer (20mM Tris--HCl, pH 7.4, 2mM EDTA, 2mM ethyleneglycotetraacetic acid, 50mM β-glycerophosphate, 1mM sodium orthovanadate, 1mM dithiothreitol, 1% Triton X-100, 10% glycerol, 10 μg/mL aprotinin, 10 μg/mL pepstatin, 1mM benzimide, and 2mM phenylmethylsulfonyl fluoride) for 30 minutes with rotation at 4°C. The lysates were clarified by centrifugation at 16,000 × *g* for 10 minutes at 4°C and stored at −20°C until needed. Whole cell lysates were then analyzed using immunoblotting analysis [@bib17]. Proteins were separated on 10% SDS-polyacrylamide gels and transferred by electroblotting to a polyvinylidenedifluoride membrane. Membranes were blocked for 1 hour in Tris-buffered saline containing 3% fetal bovine serum, 20mM NaF, 2mM EDTA, and 0.2% Tween 20 at room temperature. The membranes were incubated for 1 hour with specific primary antibodies at 4°C, washed three times with the same buffer, and incubated for an additional 1 hour with horseradish-peroxidase-conjugated secondary antibodies. The total and phosphorylated levels of Apo-A1, c-PARP, p85/phosphoinositde 3-kinase, AKT, extracellular signal-regulated kinase, Src, p65/nuclear factor-κB, p53, and β-actin were visualized using an ECL system (Amersham, Little Chalfont, Bucks, UK), as reported previously [@bib18; @bib19].

2.9. Statistical analysis {#sec2.9}
-------------------------

Data are expressed as the mean ± standard error of the mean. For statistical comparison, results were analyzed using analysis of variance and Student\'s *t* test. A *p* value \< 0.05 was considered statistically significant. All statistical tests were carried out using the computer program STATISTICA version 4.5 (StatSoft Inc., Tulsa, OK, USA).

3. Results and discussion {#sec3}
=========================

To understand the mode of action of the antiproliferative and proapoptotic activities of G-Rp1, we first examined whether G-Rp1 was able to block the proliferation of LoVo colorectal cancer cells. As shown in [Fig. 2](#fig2){ref-type="fig"}A, G-Rp1 dose-dependently suppressed up to 70% of the proliferation of LoVo cells at 60μM. Although the antiproliferative activity of G-Rp1 in colorectal cancer cells is weaker than in human breast cancer cells [@bib9], the inhibition of LoVo cell proliferation by G-Rp1 indicates that this compound may have common antiproliferative activity regardless of the cell type. Indeed, PI staining strongly implied that the G-Rp1-induced antiproliferative activity was due to the induction of proapoptotic activity by this compound. Thus, G-Rp1 treatment dose- and time-dependently enhanced DNA fragmentation as assessed by PI staining ([Fig. 2](#fig2){ref-type="fig"}B), similar to that observed in previous studies [@bib9; @bib20].

Unlike previous approaches that have examined apoptosis-inducing mechanisms of G-Rp1 [@bib20], this study used proteomic analysis to determine the mode of action of G-Rp1. As [Fig. 3](#fig3){ref-type="fig"}A depicts, many proteins bands could be detected in LoVo cells using 2-DE. After preparing whole cell lysates with G-Rp1-treated LoVo cells, the blotting patterns between these samples were compared. As shown in [Fig. 3](#fig3){ref-type="fig"}A, most band patterns appeared similar, although several bands (indicated with white arrows in [Fig. 3](#fig3){ref-type="fig"}A) were strikingly increased in G-Rp1-treated cells. To determine which bands showed higher expression patterns, we further analyzed the biochemical properties of these bands using proteomic analysis. As [Fig. 3](#fig3){ref-type="fig"}B indicates, the bands were revealed to be Apo-A1; a major component of high-density lipoprotein that regulates reverse cholesterol transport by modulating the levels of cholesterol and phospholipids in cells [@bib21], and helps control inflammatory responses and oxidative stress [@bib22]. The induction level of Apo-A1 in G-Rp1-treated LoVo cells was also confirmed by immunoblotting analysis of other cancer cells such as SNU-407, DLD-1, SNU-638, AGS, KPL-4, and SK-BR-3. Thus, [Fig. 4](#fig4){ref-type="fig"} clearly indicates that the protein level of Apo-A1 was strikingly enhanced with G-Rp1 treatment, suggesting its involvement in the mechanism of action of G-Rp1.

To evaluate further the regulatory mechanism of G-Rp1-mediated apoptosis, small-interfering (si)RNA for Apo-A1 was introduced into the G-Rp1-treated LoVo cells. As shown in [Fig. 5](#fig5){ref-type="fig"}A, c-PARP and p53 were enhanced in siApo-A1-treated cells in the presence of G-Rp1, implying that these proteins might participate in G-Rp1-induced apoptotic activity. Indeed, siApo-A1 treatment decreased the cell proliferation capacity of LoVo cells, although there was no significant difference ([Fig. 5](#fig5){ref-type="fig"}B). Importantly, the level of c-PARP in normal cells under siApo-A1 exposure was clearly upregulated, suggesting that Apo-A1 acts as an apoptosis-preventing protein. Indeed, it was proposed that Apo-A1 might act as a regulator of tumor growth and metastasis [@bib23]. However, considering that Apo-A1 is highly expressed in primary cancer cells rather than just in the secondary state [@bib24], it is possible that this protein is involved in reversing malignant cells back into a normal cycle of differentiation. Recent findings that Apo-A1 is capable of promoting the cardiac differentiation of embryonic stem cells and inducing pluripotent stem cells [@bib25] support this assumption. Therefore, our data and those of previous reports suggest that Apo-A1 is involved in the antiproliferative and proapoptotic activities of G-Rp1, via regulation of cancer cell differentiation. Relevant hypotheses regarding the functional role of Apo-A1 in G-Rp1-mediated anticancer activity will be further tested in upcoming projects.

In summary, we have demonstrated that G-Rp1 is capable of suppressing the proliferation of colorectal cancer cells and enhancing their apoptosis via enhanced levels of Apo-A1. The protein levels of c-PARP and p53 were enhanced under siApo-A1 treatment, therefore, the Apo-A1-mediated anticancer effect of G-Rp1 might be linked to the functional involvement of these proteins, as summarized in [Fig. 6](#fig6){ref-type="fig"}. Future studies will examine the exact molecular mechanism of Apo-A1-dependent G-Rp1 pharmacology in terms of its differentiation-inducing activities.

Conflicts of interest {#sec4}
=====================

The authors report no conflict of interests.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

![The chemical structure of ginsenoside-Rp1.](gr1){#fig1}

![The effect of G-Rp1 on cell proliferation and DNA fragmentation. (A) LoVo cell proliferation was determined by a conventional MTT assay. (B) Flow-cytometric cell cycle analysis of untreated and G-Rp1-treated cells was performed by propidium iodide staining. LoVo (10^6^) cells were exposed to 1.5mM hydroxyurea for 14 hours and then treated with G-Rp1 for 12 hours and 24 hours. Cell samples were analyzed for DNA content by flow cytometry. Data are presented as the mean ± standard error of the mean of three independent observations performed in triplicate. \**p* \< 0.05 compared to normal group. G-Rp1 = ginsenoside-Rp1; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.](gr2){#fig2}

![Identification of G-Rp1-inducible proteins in LoVo cells. (A) 2-DE gel images showing differential protein levels between normal LoVo or G-Rp1-treated LoVo cells. Enlarged 2-DE gel images demonstrate that the proteins indicated by the white arrows were significantly up-regulated in G-Rp1-treated LoVo cells. (B) Identification of Apo-A1 by MALDI-MS analysis. The protein indicated in [Fig. 2](#fig2){ref-type="fig"}A was unambiguously identified as Apo-A1. Mass analysis data are shown in the table. 2-DE = two-dimensional gel electrophoresis; MALDI-MS = Matrix-assisted laser desorption/ionization mass spectrometry; Apo-A1 = apolipoprotein-A1; G-Rp1 = ginsenoside-Rp1.](gr3){#fig3}

![Determination of Apo-A1 level in G-Rp1-treated cancer cells. (A, B) Cells were incubated with G-Rp1 for 48 hours. Total levels of Apo-A1 and β-actin in total lysates were determined by immunoblotting analysis. Apo-A1 = apolipoprotein-A1; G-Rp1 = ginsenoside-Rp1.](gr4){#fig4}

![Effect of siApo-A1 in G-Rp1-treated cancer cells. (A) The effect of siApo-A1 treatment was evaluated by analyzing major signaling molecules and transcription factors in LoVo cells by immunoblotting analysis. (A) The proliferation of siApo-A1-treated LoVo cells was determined by a conventional MTT assay. Data are presented as the mean ± standard error of the mean of three independent observations, performed in triplicate. siApo-A1 = small interfering apolipoprotein-A1; G-Rp1 = ginsenoside-Rp1; MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.](gr5){#fig5}

![Schematic diagram of ginsenoside-Rp1 action.](gr6){#fig6}
